Diagnostics Aimed At Practical Treatment Choices
Nuvera's initial offering is aimed at differentiation and selection of treatments in breast cancer leading to higher response from chemotherapy and endocrine therapy and better rates of survival among treated patients. The Company is working closely with leading cancer centers worldwide to validate the predictive test and help its introduction to the clinical laboratory as a diagnostic service.
Nuvera's technology platform and the clinical expertise of its partners provide a significant capability for development of companion diagnostics to cancer drugs. The Company's vision is to develop a broad portfolio of clinically validated tests for therapy response, staging and prognosis based on an efficient molecular testing platform.
For detailed program descriptions, please contact us.